Phase 3 study of SGX301 and fluorescent light for cutaneous t cell lymphoma
Ended Cooperative Agreement Awarded Last action
- Award ID
- R44CA210848
- Recipient
-
Soligenix, Inc. UEI GVD4XBVYD9J5
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,500,000
Award facts
- Assistance listing
- 93.395 Cancer Treatment Research
- Completion date
- Originally
- Place of performance
- Princeton, NJ, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $750,000 | |
| Original award | $750,000 |
Quick answers
Who received award R44CA210848?
R44CA210848 was awarded to Soligenix, Inc. by National Cancer Institute (National Institutes of Health) on September 14, 2017.
How much is award R44CA210848 worth?
$1,500,000 has been obligated on R44CA210848.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award